Insud Pharma announced today that it has entered into an agreement with Fresenius Kabi. Under the terms of the agreement Fresenius Kabi will acquire 55% of mAbxience, the global fully-fledged biotech company of the Spanish group.
Insud Pharma and Fresenius Kabi combine efforts to accelerate the growth of mAbxience
